Integrating Ancillary Systems – A Bridge To Closed Cell Therapy Manufacturing Processes

As the industry begins to think broader around scalable manufacturing for cell and gene therapy (CGT), the closing and automation of upstream material and systems that feed into the core process has become critical, and importantly – now technologically possible. These ancillary processes such as media formulation, viral vector filling and packaging are all part of the labor-intensive formula that are entering into a period of innovation and automation.

While the initial focus was on the closed, integrated and automated core processes, the ancillary processes remain open. The next phase of growth in the CGT industry is expanding automation into these processes. Although lessons can be learned from the current biopharmaceutical sector, the material and packaging requirements for CGT are unique. As a response to this need, platforms have been established to support the specific needs of this industry.